Access Curated Private Market Opportunities
Award-winning Platform Empowering Innovation, Capital and Ambition, Globally
-
0
+
Investors & Deal Makers
-
0
Unicorns
-
0
Year track record
POWERED BY CapitalHQTM
Utilise our cutting-edge AI-powered platform to access curated Private Opportunities. Discover Startups, Scaleups, Fund Managers, Private Equity, Property, Small Cap Listed and Secondary Market Opportunities
Join an exclusive ecosystem of High-Net-Worth, Professional, Institutional, VC and Family Office Investors. Receive personalised deal flow, streamlined information access and access to investment insights from leading global Fund Managers and Investors
Access Exclusive Private Opportunities
Get access to curated growth companies, property opportunities, alternative funds, investment insights and exclusive investor networking events
- Free Account Set up
- No transaction fees
- Direct Access to CEOs and Managers
- Curated Global Deal Flow
QBiotics Group
The Insides Company
NanoFynd Pty Ltd
Elemental IV
SoHi Partners
A Personalised Pipeline of Opportunities
Let our AI/ML provide you with personalised, exclusive and consistent deal flow
QBiotics Group
The Insides Company
NanoFynd Pty Ltd
Elemental IV
SoHi Partners
- Overview
- Market Opportunity
- Competitive Advantage
- Highlights and Milestones
- Investment Offering
Streamlined Investor Experience
Access the information you want and need, in a structured, clear format.
Trusted by hundreds of companies worldwide
Our international clientele includes leading emerging growth companies, funds, governments, universities, incubators, accelerators and advisory firms.
Premier Investor Events and Conferences
See exclusive pitches, product demos, and talk with founders
In person or online
Wholesale Investor Year-End Showcase 2026 | Online Investor Event
Emergence 2027: The Acceleration – Sydney
As seen in
News and announcements
Our Clients’ Major Breakthrough and Milestones
A$5 trillion market Australians can see but cannot easily buy
Every asset class now carries artificial intelligence exposure, including the ones built to be defensive. Capital47’s argument is that every portfolio should have a diversification strategy. The problem with AI as a portfolio exposure is that it has stopped being a sector. Planned global spending on artificial intelligence is expected to run to US$8 trillion […]
The A$20.4 Million Inertia Trap: How Kepa Software Is Unlocking Value in Enterprise Capital Allocation
A government agency renewed the same maintenance decision nine years running, because auditing the original choice was deemed too expensive. When the portfolio was finally tested, A$20.4 million of low value spend was identified in a single year. Kepa Software’s capital governance platform was built to expose and eliminate precisely these boardroom blind spots. For […]
The prefab company that deliberately leaves part of the house unbuilt
BuiltQuik prefabricates the floor and roof structure and stops there. Co-founder Ryan Mullaney argues the omission is the product. Prefabricated housing usually means a factory. A large central facility, identical modules, limited room to move on design, and a logistics problem getting the finished box to site. BuiltQuik builds the opposite, and the design decision […]
Dogs First to Reduce Risk: QBiotics’ Smarter Path to Oncology Markets
QBiotics took a compound derived from a north Queensland rainforest tree all the way to veterinary registration before pursuing human oncology to de-risk its human cancer programme. Interim CEO Ebru Davidson argues that sequence – now backed by early responses across several human cancers – is the company’s real asset. The story that pulled Wholesale […]
See more exiting opportunities on CapitalHQ
Pictor
Powering diagnostics with protein signatures. Pictor is transforming health with its patented platform providing accessible, affordable, and scalable diagnostic solutions across the human and animal health verticals. PictArray can detect up to 10 diseases or biomarkers from one small serum, milk,…
HorizonTwo Capital Partners
HorizonTwo Capital Partners is a private equity firm that specialises in advanced manufacturing companies.
The Insides Company
First-in-class medtech for intestinal failure. Seeking remaining $1M of a $5M round, on a AUD$17.2M pre-money valuation.
DCARB
We are aiming to raise $CAD5M to fund the ongoing commercialisation of the D100 unit, including working capital to fund the expected growth in sales, and a field trial of the DArc unit. This follows a successful Series B round completed in mid-2023.
Grabba Technologies Pty Ltd
Advanced manufacturer of biometric identity authorisation products and electronics supplier to defence industry. We invite expressions of interest for up to $10.0M in growth capital.
Backed By Leading Investment Groups and Family Offices
